Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

$2.2B

Market Cap • 4/3/2025

1989

(36 years)

Founded

1997

(28 years ago)

IPO

NASDAQ

Listing Exchange

Flag of US

Cambridge

Headquarters • Massachusetts